Back to Search Start Over

Modeling 1-Cyano-4-Dimethylaminopyridine Tetrafluoroborate (CDAP) Chemistry to Design Glycoconjugate Vaccines with Desired Structural and Immunological Characteristics.

Authors :
Nappini R
Alfini R
Durante S
Salvini L
Raso MM
Palmieri E
Di Benedetto R
Carducci M
Rossi O
Cescutti P
Micoli F
Giannelli C
Source :
Vaccines [Vaccines (Basel)] 2024 Jun 24; Vol. 12 (7). Date of Electronic Publication: 2024 Jun 24.
Publication Year :
2024

Abstract

Glycoconjugation is a well-established technology for vaccine development: linkage of the polysaccharide (PS) antigen to an appropriate carrier protein overcomes the limitations of PS T-independent antigens, making them effective in infants and providing immunological memory. Glycoconjugate vaccines have been successful in reducing the burden of different diseases globally. However, many pathogens still require a vaccine, and many of them display a variety of glycans on their surface that have been proposed as key antigens for the development of high-valency glycoconjugate vaccines. CDAP chemistry represents a generic conjugation strategy that is easily applied to PS with different structures. This chemistry utilizes common groups to a large range of PS and proteins, e.g., hydroxyl groups on the PS and amino groups on the protein. Here, new fast analytical tools to study CDAP reaction have been developed, and reaction conditions for PS activation and conjugation have been extensively investigated. Mathematical models have been built to identify reaction conditions to generate conjugates with wanted characteristics and successfully applied to a large number of bacterial PSs from different pathogens, e.g., Klebsiella pneumoniae , Salmonella Paratyphi A, Salmonella Enteritidis, Salmonella Typhimurium, Shighella sonnei and Shigella flexneri . Furthermore, using Salmonella Paratyphi A O-antigen and CRM <subscript>197</subscript> as models, a design of experiment approach has been used to study the impact of conjugation conditions and conjugate features on immunogenicity in rabbits. The approach used can be rapidly extended to other PSs and accelerate the development of high-valency glycoconjugate vaccines.

Details

Language :
English
ISSN :
2076-393X
Volume :
12
Issue :
7
Database :
MEDLINE
Journal :
Vaccines
Publication Type :
Academic Journal
Accession number :
39066345
Full Text :
https://doi.org/10.3390/vaccines12070707